Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1

American Journal of Clinical Pathology

Volumn 127, Issue 4, 2007, Pages 633-641

  Smith, Justine R ^a   Falkenhagen, Katherine M ^a   Coupland, Sarah E ^c   Chipps, Timothy J ^a   Rosenbaum, James T ^a,b   Braziel, Rita M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

B cell; CCL20; CXCL12; CXCR4; Immunohistochemistry; Primary central nervous system lymphoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BRAIN BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PHENOTYPE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; BRAIN NEOPLASMS; CHEMOKINES, CC; CHEMOKINES, CXC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MACROPHAGE INFLAMMATORY PROTEINS; MALE; MIDDLE AGED; RECEPTORS, CXCR4;

EID: 34247141490     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/NUQHJ79BHWYD9TAF     Document Type: Article

References (41)

1. Freilich RJ, DeAngelis LM. Primary central nervous system lymphoma. Neurol Clin. 1995;13:901-914.
2. Plotkin SR. Update on primary central nervous system lymphoma. Curr Opin Neurol. 2005;18:645-653.
3. Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11:285-295.
4. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2002;95:1504-1510.
5. Diamond C, Taylor TH, Aboumrad T, et al. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer. 2006;106:128-135.
6. Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005;19:611-627, v.
7. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51-61.
8. Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101:139-145.
9. Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63:901-903.
10. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 2006;79:639-651.
11. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68:835-853.
12. Von Andrian UH. Introduction: chemokines: regulation of immune cell trafficking and lymphoid organ architecture. Semin Immunol. 2003;15:239-241.
13. Smith JR, Braziel RM, Paoletti S, et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101:815-821.
14. Casamayor-Palleja M, Mondiere P, Amara A, et al. Expression of macrophage inflammatory protein-3alpha, stromal cell-derived factor-1, and B-cell-attracting chemokine-1 identifies the tonsil crypt as an attractive site for B cells. Blood. 2001;97:3992-3994.
15. Page G, Miossec P. Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol. 2004;204:28-38.
16. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004;5:943-952.
17. Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184:1101-1109.
18. Lazarini F, Tham TN, Casanova P, et al. Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia. 2003;42:139-148.
19. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
20. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761-1767.
21. Chan CC, Shen D, Hackett JJ, et al. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology. 2003;110:421-426.
22. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev. 2000;177:175-184.
23. Klein RS, Rubin JB. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 2004;25:306-314.
24. Pashenkov M, Soderstrom M, Link H. Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inflammation. J Neuroimmunol. 2003;135:154-160.
25. Giunti D, Borsellino G, Benelli R, et al. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol. 2003;73:584-590.
26. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2004;101:11064-11069.
27. Ambrosini E, Remoli ME, Giacomini E, et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol. 2005;64:706-715.
28. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129:200-211.
29. Rostasy K, Egles C, Chauhan A, et al. SDF-1alpha is expressed in astrocytes and neurons in the AIDS dementia complex: an in vivo and in vitro study. J Neuropathol Exp Neurol. 2003;62:617-626.
30. Mazzucchelli L, Blaser A, Kappeler A, et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest. 1999;104:R49-R54.
31. Husson H, Freedman AS, Cardoso AA, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol. 2002;119:492-495.
32. Mori M, Manuelli C, Pimpinelli N, et al. BCA-1, a B-cell chemoattractant signal, is constantly expressed in cutaneous lymphoproliferative B-cell disorders. Eur J Cancer. 2003;39:1625-1631.
33. Kimura R, Nishioka T, Ishida T. The SDF1-G801A polymorphism is not associated with SDF1 gene expression in Epstein-Barr virus-transformed lymphoblastoid cells. Genes Immun. 2003;4:356-361.
34. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia. 2001;36:118-124.
35. Wu DT, Woodman SE, Weiss JM, et al. Mechanisms of leukocyte trafficking into the CNS. J Neurovirol. 2000;6(suppl 1):S82-S85.
36. Alter A, Duddy M, Hebert S, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol. 2003;170:4497-4505.
37. Dunussi-Joannopoulos K, Zuberek K, Runyon K, et al. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood. 2002;100:1551-1558.
38. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91:2305-2309.
39. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655-2663.
40. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005;115:86-93.
41. Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 2002;62:3106-3112.